Company Overview and News


Add ONTX
to your dashboard

Headline News

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

2017-11-16 reuters
* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage: (26-0)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (43-0)

Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi

2017-10-10 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

2017-09-21 reuters
* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates (43-0)

Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q2 2017 Results - Earnings Call Transcript

2017-08-15 seekingalpha
Good morning, and welcome to Onconova’s Second Quarter 2017 Earnings Call and Webcast. At this time, all participants have been placed on listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. [Operator instructions]

BRIEF-Onconova Therapeutics announces research and clinical programs evaluating rigosertib in pediatric “rasopathies”

2017-07-25 reuters
* Onconova Therapeutics announces establishment of collaborative research and clinical programs evaluating rigosertib in pediatric “rasopathies”

Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q1 2017 Results - Earnings Call Transcript

2017-05-15 seekingalpha
Good morning, ladies and gentlemen and welcome to the Onconova Therapeutics Full-Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

Marriott International Inc (MAR) Leads 17 Notable Investor Filings

2017-05-03 investorplace
When a person or group of persons acquires beneficial ownership of more than 5% of a company’s equity securities, they are required to file a Schedule 13D or 13G with the SEC.

BRIEF-Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics

2017-05-01 reuters
* Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics Inc as of April 21 - sec filing Source text : bit.ly/2oQ05LT Further company coverage: (0-1)

BRIEF-Onconova Therapeutics reports proposed public offering of common stock

2017-04-21 reuters
* Onconova Therapeutics Inc - intends to use net proceeds from offering to support development of rigosertib for treatment in higher risk mds Source text for Eikon: Further company coverage: (0-1)

Onconova Has Fascinating Science, Huge Speculative Potential, And Very Little Cash

2017-04-18 seekingalpha
The drug failed an earlier trial, but saw good results in a subgroup for the IV formulation.

Company News for April 05, 2017

2017-04-05 zacks
•    General Communication, Inc.’s shares advanced 62.4% after Liberty Interactive Corporation (LVNTA - Free Report) revealed plans to acquire General Communication for $1.12 billion •    Shares of Acuity Brands, Inc. (AYI - Free Report) fell 2.2% after reporting second-quarter fiscal 2017 adjusted earnings of $1.65 per share, missing the Zacks Consensus Estimate of $1.70 •    RedHill Biopharma Ltd’s (RDHL - Free Report) shares advanced 4.

CUSIP: 68232V108